Exchange: NYSE·Updated 07:34 PM EDT
News
all
press releases
IQV Stock Gains 42% in 3 Months: Here's What You Should Know
IQVIA shares jump 41.5% in three months as record R&DS bookings, a solid backlog, raised 2026 guidance and share buybacks support sentiment.
Zacks
More News
Why IQVIA Holdings (IQV) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks
IQVIA Holdings (IQV) is a Top-Ranked Momentum Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks
Is ICON a Buy as Valuation Improves but Earnings Risks Still Persist?
ICLR's discounted valuation and $23.4B backlog support upside potential, but falling estimates, weaker margins and execution risks argue for patience.
Zacks
FISV Q2 Earnings Miss Estimates on Margin Pressure, Revenues Decline
Fiserv's Q2 revenues miss estimates and margin pressure leads to an earnings miss and cuts in its 2026 growth and profit outlook.
Zacks
Is MEDP Worth Buying as Growth Collides With a Premium Valuation?
Medpace pairs double-digit growth, record awards and a strong balance sheet with a rich valuation, raising the question of whether the premium already prices in its outlook.
Zacks
ICLR Jumps 33.2% in Three Months as Recovery Expectations Strengthen
ICON's 33.2% rally is backed by stronger proposal flow, bookings and backlog, but weaker earnings and margins cloud the recovery.
Zacks
Can MEDP's Record Q2 Bookings Build a Stronger Growth Path for 2027?
Medpace posted record Q2 awards and a stronger book-to-bill ratio, but can backlog conversion and study timing turn renewed demand into stronger 2027 growth?
Zacks
IQVIA and Medera to Advance Cardiac Gene Therapy and Human-Based Drug Discovery
IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, and Medera Inc. (Medera), a clinical-stage biopharmaceutical company pioneering next-generation therapeutics for cardiovascular...
Business Wire
Is IQVIA Stock a Buy as Growth Improves but High Leverage Persists?
IQV's proprietary data platform and expanding clinical research business support growth, but high debt and liquidity risks keep the investment outlook balanced.
Zacks

Advertisement|Remove ads.